Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | MicrobiomeTrials
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-01-18Est. Completion: 2027-12-01
Enrollment target: 70 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States